Humacyte
Total Raised
$438.81MInvestors Count
14Deal Terms
3Funding, Valuation & Revenue
11 Fundings
Humacyte has raised $438.81M over 11 rounds.
Humacyte's latest funding round was a PIPE for $10M on May 12, 2023.
Humacyte's valuation in February 2021 was $800 - $1,100M.
Humacyte's latest post-money valuation is from February 2021.
Sign up for a free demo to see Humacyte's valuations in June 2018 and more.
Humacyte's 2021 revenue was $1.26M. Humacyte's most recent revenue is from 2020.
Sign up for a free demo to see revenue data from 2023, 2021, 2020 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
5/12/2023 | PIPE | $10M | 1 | |||
8/30/2021 | Corporate Minority - P2P | $25M | $1.26M FY 2021 | 8 | ||
2/17/2021 | Reverse Merger | $800 - $1,100M | 7 | |||
4/27/2020 | Loan | |||||
6/11/2018 | Corporate Minority |
Date | 5/12/2023 | 8/30/2021 | 2/17/2021 | 4/27/2020 | 6/11/2018 |
|---|---|---|---|---|---|
Round | PIPE | Corporate Minority - P2P | Reverse Merger | Loan | Corporate Minority |
Amount | $10M | $25M | |||
Investors | |||||
Valuation | $800 - $1,100M | ||||
Revenue | $1.26M FY 2021 | ||||
Sources | 1 | 8 | 7 |
Humacyte Deal Terms
3 Deal Terms
Humacyte's deal structure is available for 3 funding rounds, including their Reverse Merger from February 17, 2021.
Round | Reverse Merger | Corporate Minority | Series B |
|---|---|---|---|
Funding Date | |||
Pre-Money Valuation | |||
Post-Money Valuation | |||
Amount Raised | |||
Shares Authorized | |||
Issuance Price | |||
Dividend Rate | |||
Liquidation Preferences | |||
Liquidation Price | |||
Participation | |||
Conversion Price | |||
Anti Dilution | |||
General Voting | |||
Board Voting | |||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Reverse Merger | |||||||||||||||
Corporate Minority | |||||||||||||||
Series B |
Humacyte Investors
14 Investors
Humacyte has 14 investors. Oberland Capital invested in Humacyte's PIPE funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
5/12/2023 | 5/12/2023 | 1 PIPE | Debt & Specialty Finance | New York | ||
6/11/2018 | 8/30/2021 | 2 Corporate Minority, Corporate Minority - P2P (2021) | Corporation | Germany | ||
2/17/2021 | 2/17/2021 | 1 Reverse Merger | SPAC | New York | ||
Government | DC | |||||
Asset/Investment Management | New York |
First funding | 5/12/2023 | 6/11/2018 | 2/17/2021 | ||
|---|---|---|---|---|---|
Last Funding | 5/12/2023 | 8/30/2021 | 2/17/2021 | ||
Investor | |||||
Rounds | 1 PIPE | 2 Corporate Minority, Corporate Minority - P2P (2021) | 1 Reverse Merger | ||
Board Seats | |||||
Type | Debt & Specialty Finance | Corporation | SPAC | Government | Asset/Investment Management |
Location | New York | Germany | New York | DC | New York |
Compare Humacyte to Competitors
EpiBone focuses on bone and cartilage reconstruction within the healthcare sector. The company specializes in creating personalized bone and cartilage products by utilizing a patient's own stem cells to cultivate defect-specific autologous-like bone grafts. It was founded in 2013 and is based in New York, New York.
KLISBio is a med-tech company. The company develops regenerative implantable products by using silk fibroins. The company leverages a silk-based technology platform to develop scaffold materials for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears, and situations where a sustained drug release is needed. It was founded in 2014 and is based in Milan, Italy.
Xeltis develops vascular implants that address diseases within the medical device industry. The company offers a platform for artificial vessels and valves that are designed to be replaced by the patient's own living tissue, which may reduce risks associated with traditional implants. Xeltis serves sectors that require vascular and valve replacement surgeries, such as hemodialysis access and coronary arterial bypass procedures. It was founded in 2006 and is based in Eindhoven, Netherlands.
Vascudyne is involved in the development and manufacturing of engineered tissues within the healthcare sector. The company provides products that include cardiovascular, vascular, neurological, wound care, and aesthetic medical solutions that are biological, regenerative, and non-immunogenic. Vascudyne's clientele includes sectors that require medical devices and therapies. It is based in Stillwater, Minnesota.
Osiris Therapeutics researches, develops, manufactures and commercializes regenerative medicine products intended to improve the health and lives of patients and lower overall healthcare costs. The company offers products in orthopedics, sports medicine and wound care, including the Grafix product line, Stravix, BIO4 and Cartiform. Osiris continues to advance its research and development by focusing on products in regenerative medicine, including the development of bioengineered stem cell and tissue‑based products. On April 17th, 2019, Osiris Therapeutics was acquired by Smith & Nephew at a valuation of $660M.
RTI Surgical is a leading Contract Development and Manufacturing Organization (CDMO) in the field of regenerative medicine, focusing on innovation and tissue engineering. The company partners with Original Equipment Manufacturers (OEMs) to develop customized medical solutions that promote healing, accelerate recovery, and prevent complications. RTI Surgical primarily serves specialized clinical segments such as breast and plastic surgery, sports medicine and orthopedics, and neuro and spine surgery. It was founded in 1997 and is based in Alachua, Florida.
Loading...